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Background
Immunotherapy for allergic rhinitis with/without conjunc-
tivitis (AR/C) may exhibit different efficacy characteristics
in patients with multiple allergen sensitizations than
monosensitized patients. It has been considered that
monosensitized patients may benefit more from immu-
notherapy than polysensitized patients. Evidence from ran-
domized, blinded, placebo-controlled trials of Timothy
grass sublingual immunotherapy tablet (SLIT-T) MK-7243
(Merck/ALK-Abelló) indicates that treatment in mono-
and polysensitized subjects is equally effective.
Methods
A prospective efficacy analysis was performed between
monosensitized and polysensitized subjects treated with
the short-ragweed SLIT-T MK-3641 (Ambrosia artemisii-
folia; Merck/ALK-Abelló). Pooled data from 2 randomized
placebo-controlled trials investigating MK-3641 (6 and 12
Amb a 1-U doses) were used. The primary efficacy out-
come was the total combined score (TCS=symptom+med-
ication scores) during the 15-day peak season.
Results
Differences versus placebo for the MK-3641 6 and 12
Amb a 1-U pooled groups (mono- and polysensitized
subjects combined) for the peak season TCS were 20%
(−1.70; 95% CI, −2.55 to −0.86) and 23% (−2.02; 95% CI,
−2.87 to −1.17), respectively (P<0.001 for both). Differ-
ences versus placebo in the monosensitized MK-3641
pool (n = 175) were 15% (−1.34; 95% CI, −3.40 to 0.73)
and 19% (−1.72; 95% CI, −3.63 to 0.20) for 6 and 12
Amb a 1-U, respectively. In the polysensitized MK-3641
pool (n = 784) difference versus placebo were 21%
(−1.78; 95% CI, −2.80 to −0.75) and 27% (−2.27; 95% CI,
−3.27 to −1.28) for 6 and 12 Amb a 1-U, respectively.
Conclusions
In the whole study population, treatment with MK-3641
6 and 12 Amb a 1-U for ragweed-induced AR/C was
superior to placebo. Although the sample size for the 2
subpopulations was not balanced and data must be
interpreted cautiously, it appears that the treatment
effect is similar in the mono- and polysensitized subpo-
pulations, with a numerical trend of a greater treatment
effect in polysensitized subjects.
Trial registration
ClinicalTrials.gov Identifiers: NCT00783198; NCT00770315.
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